Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Statistics in Medicine|April 2, 2026
Randomization-Based Covariance Analysis for Confidence Intervals of Treatment Comparisons Based on Restricted Mean Survival Time With Categorized Time-to-Event DataTaylor Krajewski, Gary KochPharmaceutical Statistics|January 12, 2017
Analyzing multiple endpoints in a confirmatory randomized clinical trial-an approach that addresses stratification, missing values, baseline imbalance and multiplicity for strictly ordinal outcomesHengrui Sun, Atsushi Kawaguchi, Gary KochTherapeutic Innovation & Regulatory Science|March 23, 2022
Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's DiseaseDeli Wang, Elaine Kearney Kowalewski, Gary KochPharmaceutical Statistics|April 10, 2014
The iterative proportional fitting algorithm for adjusted agreement in a non-inferiority diagnostic clinical trialJill Ann El-Khorazaty, Gary Koch, John PreisserTherapeutic Innovation & Regulatory Science|April 2, 2021
Design and Analysis of a Biosimilar Bridging Study with a Prediction Interval-Based Consistency TestZhiying Pan, Wenying Huang, Jianhong Pan, et al.Pharmaceutical Statistics|May 5, 2017
Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case studyJohn Ouyang, Kevin J Carroll, Gary Koch, et al.American Journal of Public Health|September 29, 2004
Retention of primary care physicians in rural health professional shortage areasDonald E Pathman, Thomas R Konrad, Rebekkah Dann, et al.Pharmaceutical Statistics|November 21, 2017
A case study in identifying targeted patients population in major depressive disorder by enhanced enrichment designPeter Zhang, Kevin Carroll, Mary Hobart, et al.Pharmaceutical Statistics|January 31, 2019
Statistical considerations in a delayed-start design to demonstrate disease modification effect in neurodegenerative disordersDeli Wang, Weining Robieson, Jun Zhao, et al.Therapeutic Innovation & Regulatory Science|December 10, 2020
Combined-Indications Significance Level of Multiple Related Indications Developed SimultaneouslyJiacheng Yuan, Ray Zhu, Daniel Jia, et al.Pageof 4